Researchers at Fred Hutch Cancer Center invented a new screening method called ReLiC that uses CRISPR-Cas9 to test all the ...

A study published in Nature shows that certain autoantibodies may influence how cancer patients respond to immunotherapy. Autoantibodies are proteins produced by the immune system and have typically ...

Ten Washington state health organizations recently received grants of up to $15,000 from Fred Hutch Cancer Center’s Community ...

In 2024, Obliteride raised more than $9 million for research at Fred Hutch, contributing to more than $58 million raised since 2013. These funds have fueled urgently needed advances in cancer ...

Dr. Folashade Otegbeye, facility director of the Therapeutic Products Program at Fred Hutch, works to rapidly translate what researchers are doing in the lab to the bedside. She is the new holder of ...

At first glance, art and science might seem like opposite worlds — one driven by imagination and emotion, the other by data ...

During his 36-year career at Fred Hutch Cancer Center, Michael Emerman, PhD, made fundamental discoveries about HIV, the retrovirus that causes AIDS. He co-founded the field of paleovirology and ...

Fred Hutch Cancer Center announces 2025 Evergreen Fund awardees, nine Fred Hutch researchers receive funding totaling $1.175 million for projects with commercial partnership potential.

Thanks to generous support and partnership from Alexandria Real Estate Equities, Inc., Fred Hutch has a new, state-of-the-art learning laboratory where high school and college students who participate ...

Hepatic artery infusion (HAI) therapy offers a new approach for people whose colorectal cancer has spread to the liver. It allows physicians to deliver chemotherapy directly to the liver at doses up ...